How Environment Shapes Treatment Engagement in Schizophrenia
Michael D. Rosberg, Ph.D.
Despite real advances in pharmacotherapy and social care models, treatment adherence remains a central challenge in schizophrenia care, especially among individuals with treatment-refractory schizophrenia (TRS). For this population, where relapse, high utilization of acute services, and functional stagnation are common, the design of the treatment environment is an underused point of leverage.
Social motivation, an important factor in adherence, is itself shaped by environment. In a systematic review of ecological momentary assessment studies, Mote and Fulford (2020) found that individuals with schizophrenia experience fluctuations in social motivation tied to environmental context. Both under-stimulating settings and chaotic, over-stimulating ones reduce participation and erode adherence. Some of this reflects the disorder itself. Green et al. (2018) argue that while social cognitive deficits are intrinsic to schizophrenia, the disconnection and loneliness that follow are shaped by environment, which is where intervention becomes possible.
ASC Treatment Group has tested this directly. In two residential programs serving TRS clients, we restructured indoor and outdoor areas to include therapeutic gardens, animal-assisted interventions, designated quiet zones, and communal art spaces. These changes led to a 54% reduction in staff interventions and a 32% drop in PRN medication use over 18 months. Residents reported improved comfort, safety, and willingness to participate in group activities. Staff noted fewer behavioral escalations and increased rapport (Rosberg et al., 2023).
What matters most here is that these changes supported not just adherence but self-determined involvement, which is closer to what recovery actually requires. When individuals experience their environment as safe, engaging, and meaningful, they are more likely to initiate and sustain treatment on their own terms. Settings that offer autonomy and voluntary opportunities for engagement shift the basic relationship between client and program. The therapeutic alliance grows stronger, and the gains that result are more likely to last.
Beyond clinical benefits, re-engineering existing facilities is also cost-effective. Rather than investing in lengthy new builds that displace residents and delay service delivery, targeted environmental improvements preserve capacity and continuity of care. Changes in layout, lighting, acoustics, and access to communal or natural spaces produce real downstream benefits: fewer behavioral crises, less staff burnout, higher satisfaction among clients and care teams.
The implications follow. Therapeutic environments belong in the category of core infrastructure rather than ancillary support. Reconfiguring existing spaces is a scalable approach that improves adherence without disrupting current operations. And the benefits extend in both directions, to the people receiving care and to the people providing it.
TRS clients account for a disproportionate share of the $343 billion annual cost of schizophrenia in the United States in 2019 (Kadakia et al., 2022). Even modest improvements in adherence can reduce hospitalizations and crisis episodes substantially, and over time can lessen the dependence on the most expensive forms of institutional care.
We urge the American Psychiatric Association and its partners to recognize therapeutic space redesign and service desirability as essential components of schizophrenia care. Environments that support safety, autonomy, and real engagement are not enhancements to treatment. They are treatment. For individuals with schizophrenia, particularly those with the most complex needs, recovery begins not only with what is prescribed but also with where care happens, and how it feels to be there.
References
Green, M. F., Horan, W. P., Lee, J., McCleery, A., Reddy, L. F., & Wynn, J. K. (2018). Social disconnection in schizophrenia and the general community. Schizophrenia Bulletin, 44(2), 242–249. https://doi.org/10.1093/schbul/sbx082
Kadakia, A., Catillon, M., Fan, Q., Williams, G. R., Marden, J. R., Anderson, A., Kirson, N., & Dembek, C. (2022). The economic burden of schizophrenia in the United States. The Journal of Clinical Psychiatry, 83(6), 22m14458. https://doi.org/10.4088/JCP.22m14458
Mote, J., & Fulford, D. (2020). Ecological momentary assessment of everyday social experiences of people with schizophrenia: A systematic review. Schizophrenia Research, 216, 56–68. https://doi.org/10.1016/j.schres.2019.10.021
Rosberg, H., Alcantar, J., Rosberg, M. D., & Flowers, C. (2023, October 12–14). Enhanced residential settings as an augmentation of clozapine pharmacotherapy for treatment-refractory schizophrenia patients [Poster presentation]. American Psychiatric Association Mental Health Services Conference, Washington, DC, United States.